Last reviewed: June 8, 2026
Last updated: June 8, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
If you're taking GLP-1 medications like semaglutide and considering pregnancy, you likely have important questions about safety and timing. Current clinical data shows that GLP-1 receptor agonists were not studied extensively in pregnant populations, which means most healthcare providers recommend pausing these medications before conception and throughout pregnancy. Understanding the evidence and planning ahead with your medical team helps you make informed decisions that protect both your health and your baby's development.
Why GLP-1 Medications Are Typically Paused During Pregnancy
GLP-1 receptor agonists like semaglutide work by mimicking a hormone that regulates blood sugar and appetite. While these mechanisms are well-understood in non-pregnant adults, the FDA has not approved GLP-1 medications for use during pregnancy because controlled studies in pregnant people have not been conducted. This absence of safety data—not evidence of harm—is why most obstetricians and endocrinologists recommend discontinuing GLP-1 therapy at least one month before attempting conception.
Animal reproduction studies with semaglutide and tirzepatide have not shown direct fetal toxicity at standard doses, but animal models do not always predict human outcomes. The conservative approach reflects standard medical practice: avoid medications with insufficient human safety data during the most vulnerable developmental window. Your healthcare provider may discuss the specific risks and benefits based on your individual medical history, particularly if you have type 2 diabetes or obesity-related conditions that require active management during pregnancy.
Planning Pregnancy: Timeline and Medical Coordination
If you are currently on compounded semaglutide injection (starting at $149/mo at PlexusDx) or any GLP-1 medication and want to become pregnant, begin this conversation with both your prescribing provider and your obstetrician at least three to six months before attempting conception. This timeline allows you to transition off GLP-1 therapy, establish alternative weight management and blood sugar control strategies if needed, and ensure your body adjusts to the medication change. Most semaglutide remains in your system for only a few weeks after your last injection, so a one-month washout period is typically adequate before trying to conceive.
During the planning phase, your medical team may recommend strategies to prevent rapid weight regain, such as structured dietary counseling, consistent physical activity, or behavioral support. Some patients find that the habits developed during GLP-1 therapy—such as increased satiety awareness and reduced cravings—persist even after stopping the medication, making the transition smoother. If you have diabetes, your provider may adjust insulin or other glucose medications to optimize control before and during pregnancy, as stable blood sugar is critical for fetal health.
Blood Sugar Control and Metabolic Health During Pregnancy
Maintaining healthy blood sugar levels during pregnancy is essential for preventing gestational diabetes and reducing risks of preterm delivery, birth complications, and long-term health problems for your child. If you have pre-existing type 2 diabetes, pregnancy increases the complexity of blood sugar management because insulin resistance naturally rises during the second and third trimesters. Your endocrinologist or obstetrician will likely increase insulin doses, monitor you more frequently with blood glucose checks or continuous glucose monitoring, and may use medications like insulin or metformin (which has a longer safety track record in pregnancy) to maintain target ranges.
Weight management during pregnancy also shifts focus from the weight loss achieved on GLP-1 therapy to weight gain within healthy guidelines—typically 25 to 35 pounds for people at a healthy baseline weight. Your healthcare provider will monitor your progress and may refer you to a maternal-fetal medicine specialist or registered dietitian with obstetric expertise if your weight history or metabolic conditions require specialized attention. The habits you build while planning pregnancy—mindful eating, regular movement, stress management—remain valuable tools for supporting both your health and your baby's development.
Breastfeeding and Resuming GLP-1 Therapy After Delivery
After delivery, the question of when to resume GLP-1 medications depends on whether you plan to breastfeed. Semaglutide and tirzepatide are large peptide molecules that are unlikely to be absorbed through breast milk in clinically significant amounts, but formal safety data in nursing infants is limited. Most lactation specialists and maternal-fetal medicine experts suggest it is probably safe to resume GLP-1 therapy after delivery if you are not breastfeeding, typically within a few weeks once you have healed from delivery and your healthcare team gives clearance.
If you choose to breastfeed, discuss the timing of GLP-1 resumption with your obstetrician and pediatrician. Some providers may recommend waiting until breastfeeding is complete or substantially reduced before restarting therapy, while others may feel comfortable with resumption based on your individual risk factors and the strength of your commitment to nursing. The postpartum period is also an opportunity to use PlexusDx's Precision Peptide Genetic Test—a $99 add-on available after your first month of treatment—to identify your genetic predispositions across 14 metabolic pathways and 150+ peptide-related insights, helping personalize your next phase of treatment after pregnancy and postpartum recovery.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is it safe to take semaglutide while trying to conceive?
Most reproductive endocrinologists recommend stopping semaglutide at least one month before attempting conception because the medication has not been studied in pregnant people. Once you stop, the medication clears your system within weeks, and you can begin trying to conceive. Discuss your specific timeline and medical history with your prescribing provider to create a personalized plan.
What happens to my weight after I stop GLP-1 therapy for pregnancy?
Many patients experience some weight regain after stopping GLP-1 medications because appetite-regulating hormones return to baseline levels. However, behavioral changes learned during treatment—such as recognizing fullness cues and managing cravings—often persist. Your healthcare team can recommend dietary strategies, physical activity adjustments, and behavioral support to minimize weight gain during the planning and pregnancy phases.
Can I use PlexusDx semaglutide injection while pregnant?
PlexusDx compounded semaglutide injection (starting at $149/mo) should be discontinued before pregnancy, as GLP-1 medications lack adequate safety data in pregnant populations. Your PlexusDx provider can discuss the timeline for stopping treatment and coordinate with your obstetrician to ensure safe transitions to alternative management strategies during pregnancy.
What if I have type 2 diabetes—how do I manage it during pregnancy without GLP-1 therapy?
Type 2 diabetes during pregnancy typically requires insulin therapy, which has decades of safety data in pregnant people. Your endocrinologist will adjust insulin doses based on frequent blood glucose monitoring and may use continuous glucose monitoring to maintain tight control. Metformin may also be considered as an adjunctive agent. The goal is stable blood sugar to protect both your health and your baby's development.
How can PlexusDx help me prepare for pregnancy while on GLP-1 therapy?
PlexusDx providers can help you plan a safe timeline for discontinuing compounded semaglutide or tirzepatide and coordinate care with your obstetrician. After delivery, the Precision Peptide Genetic Test ($99 add-on) can reveal your unique peptide-pathway predispositions across 14 metabolic pathways, personalizing your GLP-1 therapy when you're ready to resume—whether that's after postpartum recovery or after breastfeeding ends.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Can You Take Ozempic for Menopause Weight Gain?
How Much Weight Can You Lose on Ozempic 0.5 mg?